Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Locally Advanced Chemoresistant Cervical Cancer by Choi, Youn Seok et al.
INTRODUCTION
In 1999, a National Cancer Institute Alert recommended
that concurrent chemoradiation should be considered instead
of radiotherapy alone in women with cervical cancer based
on the results of five randomized trials (1-5). A subsequent
systematic review and meta-analysis of data presented in the
previous literature have suggested a large benefit of concurrent
chemoradiation for survival, as well as local and distant con-
trol rates (6). Thus, concurrent chemoradiotherapy has become
a new ‘standard of care’ for a locally advanced cervical cancer.
However, clinical dilemma might be faced with in young
patients with bulky stage IB to IIA diseases. This is due to
that these patients might lose their sexual functions by either
concurrent chemoradiotherapy or post-operative radiotherapy.
Most investigators agree that cervical tumor size is a sig-
nificant negative prognostic factor, since bulky tumors are
associated with a high incidence in lymph node metastasis
as well as in recurrence, as compared to smaller sized tumors
(7, 8). Until now, the best treatment option for bulky stage
IB, IIA cervical cancer is uncertain. As one of treatment stra-
tegies in bulky stage IB, IIA cervical cancer, neoadjuvant
chemotherapy is an attractive option as chemotherapy given
prior to surgery can reduce tumor size leading to improve-
ment of overall survival. Several randomized controlled stud-
ies have shown survival benefits of neoadjuvant chemother-
apy followed by radical surgery in locally advanced cervical
cancer (9-12). ‘The neoadjuvant chemotherapy for cervical
cancer meta-analysis collaboration study group’ conducted a
meta-analysis from 21 randomized trials of neoadjuvant che-
motherapy settings (13), in which little survival benefit was
observed in the 18 randomized trials of neoadjuvant chemo-
therapy followed by radiotherapy. However, 5 randomized
controlled studies of neoadjuvant chemotherapy followed by
radical surgery showed survival benefits. However, this is yet
to be confirmed as the disease stages are heterogeneous and
in one trial intra-arterial chemotherapy is used. Furthermore,
in two trials post-operative radiotherapy was used in almost
all patients.
If neoadjuvant chemotherapy followed by radical surgery
offers survival benefits in cervical cancer patients, this might
be of great benefit especially to young patients with bulky
cervical carcinoma stage IB to IIA. This is because the reduc-
tion of tumor size is associated with a decrease in the frequency
of post-operative adjuvant radiotherapy, which causes the loss
of sexual functions. Since 1989, our group has started neoad-
juvant chemotherapy to treat patients with locally advanced
cervical cancer. In patients with stage IB to IIA cervical can-
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Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical
Surgery versus Radiotherapy in Locally Advanced Chemoresistant
Cervical Cancer
The aim of this study was to analyze long-term survivals in patients with stage IB
to IIA cervical cancer treated by neoadjuvant chemotherapy setting. Between Febru-
ary 1989 and January 1998, 94 women with previously untreated stage IB to IIA
carcinoma of the uterine cervix who received cisplatin based neoadjuvant chemo-
therapy were enrolled in this study. All of patients with chemoresponse (complete
response, n=15; partial response, n=47) and 16 patients with chemoresistance
received radical surgery (RS group). The other 16 patients with chemoresistance
received radiotherapy for definite treatment (RT group). In the RS group, the 10 yr
survival estimation in patients with bulky tumors (diameter ≥ ≥4 cm, n=26) was similar
to that with non-bulky tumors (83.3% vs. 89.3%, p=NS). In selected patients with
chemoresistance, those treated by radiotherapy (n=16) showed significantly poor-
er survivals than those treated by radical surgery (n=16) [10 yr survival rates of RT
(25%) vs. RS (76.4%), p=0.0111]. Our results support that a possible therapeutic
benefit of neoadjuvant chemotherapy plus radical surgery is only in patients with
bulky stage IB to IIA cervical cancer. In cases of chemoresistance, radical surgery
might be a better definite treatment option.
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cer showing poor chemoresponse, either radical surgery or
radiotherapy after neoadjuvant chemotherapy has been used
without any definite criteria under the assumption that either
one could offer similar outcomes. In this retrospective study,
we evaluated the impact on survival of neoadjuvant chemo-
therapy followed by radical surgery. We analyzed the survival
difference between radical surgery and radiotherapy after che-
motherapy in selected patients with poor chemoresponse.
MATERIALS AND METHODS
Patients
From February 1989 through January 1998, 94 patients with
International Federation of Gynecology and Obstetrics (FIGO)
stage IB or IIA cervical carcinoma (squamous, adeno- or ade-
nosquamous) treated with neoadjuvant chemotherapy followed
by radical surgery or radiotherapy were enrolled into this ret-
rospective study. Eligible criteria were 1) previously untreat-
ed, 2) FIGO stage IB to IIA, 3) received 2 or 3 cycles of cis-
platin based neoadjuvant chemotherapy, 4) non small cell car-
cinoma, 5) treated by radical hysterectomy with bilateral pelvic
lymphadenectomy or radiotherapy following neoadjuvant
chemotherapy.
Treatment
All eligible patients received cisplatin intravenous infu-
sion (100 mg/m2) on day 1, and 5-fluorouracil intravenous
infusion (1,000 mg/m2/day) for 4 days from day 2. Two or 3
cycles of chemotherapy were done at 21 days intervals, accord-
ing to chemoresponse or performance status. Three to four
weeks after the last chemotherapy, patients underwent a type
III radical hysterectomy with bilateral pelvic lymphadenec-
tomy or radiotherapy. Postoperative radiotherapy was usually
prescribed when parametrial extension or positive surgical
margins, deep stromal invasion, and lymph node metastasis
were detected. Postoperative adjuvant radiotherapy consisted
of external radiation by 10 MeV to the whole pelvis of 45 Gy
(1.8 Gy/fraction) with a parametrial boost up to 50 Gy with
a 4 cm wide midline block. Para-aortic extended field radia-
tion of 45 Gy was administrated if there were multiple, bilat-
eral pelvic, or common iliac node metastases. Patients with
poor chemoresponse (stable disease or progressive disease)
also received radical surgery as described above, or received
radiotherapy for a definite therapy without specific criteria.
Radiotherapy for definite therapy was constituted external
beam radiation followed by brachytherapy. The pelvis was
treated by external beam radiotherapy with a linear acceler-
ator using photon beam energy of 10/25 MeV within a stan-
dard four-field box technique, followed by high dose rate
brachytherapy. Patients received a dose of 4,500-5,040 cen-
tigrays (cGy) as external beam in 25-28 fractions over 5.0-5.5
weeks. This was followed by six courses of intracavitary bra-
chytherapy, after external beam radiotherapy was completed.
A dose of 3,000 cGy in 6 fractions was given over 3 weeks. 
Evaluation of tumor response
Tumor size was assessed by pelvic examination immediately
before each chemotherapy cycle and also at surgery. The clini-
cal response to chemotherapy was evaluated according to the
World Health Organization (WHO) criteria (14). Response
was measured as the product of the two largest perpendicu-
lar diameters of the cervical mass lesion. Patients were eval-
uated for response using the following criteria. A complete
response (CR) was defined as the complete disappearance of
all clinically detectable disease. A 50% or more decrease in
tumor size constituted a partial response (PR). Stable disease
(SD) was defined as no significant change in tumor size, and
progressive disease (PD) was defined as a increase of ≥25%
in tumor size or the appearance of new lesions. 
Three weeks after the last chemotherapy, the final clinical
response to chemotherapy was evaluated according to the
tumor size assessed by pelvic examination and imaging study.
Some of patients underwent radical surgery after 2 cycles of
chemotherapy due to good chemoresponse (CR or nearly CR).
Definition of endpoints and follow up
Overall survival, as the primary endpoint, was defined as
the time from date of the start of neoadjuvant chemotherapy
until death (from cervical cancer related). Surviving patients
were censored on the date of last follow-up. After treatment,
we followed up patients at 3 month intervals for the first 2
yr, and then at 4-6 month intervals for additional 3 yr, there-
after once a year. For a long term survival analysis, we inves-
tigated death date of all enrolled patients with helps from
Namgu Ward Office, Daegu, Korea, and confirmed the cause
of death by telephone or medical record review.
Statistical analysis
Survival curves were plotted according to the estimate of
Kaplan and Meier. The log-rank test was used to determine
the significance of differences in survival distribution. Odds
ratio and 95% confidence intervals of mortality from cancer
were calculated by Cox regression hazard model to determine
confounding effects of prognostic factors. The chi-square test,
independent t-test, ANOVA (analysis of variance), Mann-
Whitney U test, and Fisher’s exact test were used to compare
covariates. All comparisons were two-sided. 
RESULTS
A total of 94 patients were enrolled in this retrospectivestudy. Mean age was 44 yr (26-64 yr), and mean tumor size
at presentation was 3.95±1.3 (2.5-7.2) cm in whole series.
Seventy eight patients of the radical surgery (RS) group (com-
plete response, n=15; partial response, n=47; stable disease,
n=16) received type III radical hysterectomy and pelvic lym-
phadenectomy with or without postoperative radiotherapy.
The other 16 patients of the radiotherapy (RT) group (stable
disease, n=16) received radiotherapy following neoadjuvant
chemotherapy (Fig. 1). The number of patients was 29, 29 and
36 for stage IB1, IB2 and IIA, respectively. Median follow-up
was 85.7 months (3.7-167.7). There was no statistical differ-
ence in age, tumor size, stage, pathologic type between the
RS and RT groups except for chemoresponse. Characteristics
of patients in both groups are summarized in Table 1.
In the RS group, 23 patients (29.5%) received post-oper-
ative adjuvant radiotherapy, and in the RT group, 2 patients
received adjuvant hysterectomy following radiotherapy. Of
32 patients who showed stable disease after neoadjuvant che-
motherapy, 16 patients received radical surgery with or with-
out post-operative radiotherapy, and the other 16 patients
received radiotherapy alone for definite therapy (Fig. 1). We
did not have any definite criteria of this arrangement of treat-
ment. 
Response to neoadjuvant chemotherapy
After neoadjuvant chemotherapy, overall clinical response
rate obtained was 66.0% (CR in 15 patients [16.0%], PR
in 47 [50.0%], SD in 32 [34.0%]). In the RS group, clini-
cal response rate obtained was 79.5% (CR in 19.2%, PR in
60.3%, SD in 20.5%). All of patients in the RT group had
stable disease. 
Survival
The median duration of follow-up was 85.7 (3.7±167.7)
months. Up to the time of this analysis, 19 patients died from
cervical cancer, whereas 1 patient died from primary lung
cancer (this patient was considered as censored data at death
date). In the RS group, 8 of 78 patients died, whereas in the
RT group 11 of 16 patients died from cervical cancer. The
overall survival of whole series, 5 yr and 10 yr survival rate
were 80.7% and 77.0%, respectively (Fig. 2). The 5 yr and
10 yr survival rates of the RS group were 90.1% and 87.5%,
respectively. In the RS group, the 10 yr survival estimation
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Cervical cancer IB-IIA
n=94
NACT with cisplatin
based chemotherapy
2-3 cycles
Chemoresponsive
(CR, PR) n=62
Radical hysterectomy
with BPND (RS) n=78
High risk factor (-) High risk factor (+)
No further treatment
n=55
Adjuvant radiotherapy
n=23
Poor chemoresponsive
(Stable) n=32
Radiotherapy
(RT) n=16
Fig. 1. Treatment and patient allocation in this study.
NACT, neoadjuvant chemotherapy; CR, complete response; PR,
partial response; RS, radical surgery group treated by neoadju-
vant chemotherapy plus radical surgery; RT, radiotherapy group
treated by neoadjuvant chemotherapy plus radiotherapy; BPND,
bilateral pelvic node dissection.
Variables
RS group
(n=78)
RT group
(n=16)
p-value
Age (yr) 44.4±9.6 42.8±9.0 NS*
Tumor diameter (cm) 3.9±1.3 4.1±1.5 NS*
Stage (No.)
IB1 24 5 NS
�
IB2 24 5
IIA 30 6
Pathologic type (No.)
SCC 66 13 NS
�
Others 12 3
Clinical chemoresponse (No.)
SD 16 16 p<0.0001
�
PR 47 0
CR 15 0
Table 1. Characteristics of patients
RS group, neoadjuvant chemotherapy followed by radical surgery group;
RT group, neoadjuvant chemotherapy followed by radiotherapy group;
NS, not statistically significant difference; SCC, squamous cell carcino-
ma; SD, stable disease; PR, partial response; CR, complete response.
*, t-test; 
� , chi-square test.
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Fig. 2. Survival estimation by Kaplan Meier’s method of whole se-
ries. Five and 10 yr survival rates were 80.7% and 77.0%, respec-
tively.
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in patients with bulky tumors (diameter ≥4 cm, n=26) was
similar to that with non-bulky tumors (83.3% vs. 89.3%,
p=NS, Table 2). 
Survival of patients with chemoresistance
The survival rates of the RT group were very poor consid-
ering their stage (5 yr survival rate, 37.5%; 10 yr survival
rate, 25.0%). This result might be due to that all of patients
in RT group were selected patients showing chemoresistance.
The most striking finding in this study was that there was a
significant survival difference between the RS group with
stable disease and the RT group with stable disease even
though they showed similar clinical characteristics (Table 3).
Prognostic factors such as lymph node metastasis, lympho-
vascular space involvement, and invasion depth could not be
compared in two groups (RS vs. RT), since surgical specimen
was not available in the patients of RT group. The 10 yr sur-
vival rates of the RS and RT groups with stable disease were
76.4% and 25.0%, respectively (p=0.0111, Fig. 3).
Variables No.
5 YSR
(%)
10 YSR
(%)
p-value
�
RS group whole series 78 90.1 87.5
Age (yr)
<45 45 97.5 97.5 0.007
≥45 33 80.3 74.1
Stage
IB1 24 86.3 86.3 NS
IB2 24 95.2 95.2
IIA 30 89.7 84.7
Tumor size in diameter
<4 cm 52 89.3 89.3 NS
≥4 cm 26 91.7 83.3
Growth pattern
Exophytic 42 87.2 81.4 NS
Endophytic 36 93.8 93.8
Cell types
SCC 66 91.5 88.4 NS
Others 12 83.3 83.3
Invasion depth*
<7 mm 29 100 100 0.012
≥7 mm 34 80.8 75.7
LVS involvement
Absent 47 97.7 97.7 0.003
Present 31 78.3 71.7
LN metastasis
Absent 66 93.4 93.4 0.003
Present 12 70.0 56.0
Resection margin
Negative 75 91.2 88.3 NS
Positive 3 66.7 66.7
Parametrial invasion
Negative 75 91.3 88.5 0.073
Positive 3 50.0 50.0
Chemoresponse
CR or PR 61 93.0 89.6 NS
Stable 17 78.1 78.1
Table 2. Kaplan Meier’s survival estimation of neoadjuvant che-
motherapy followed by radical surgery according to prognostic
factors
YSR, year survival rate; RS, radical surgery; NS, not statistically signifi-
cant difference; SCC, squamous cell carcinoma; LVS, lymphovascular
space; LN, lymph node; CR, complete response; PR, partial response.
*, Total number of patients was not 78, because there were some miss-
ing data in pathologic report; 
� , Log rank test.
Variables
SD in RS
(n=16)
SD in RT
(n=16)
p-value
Age (yr) 43.3±11.5 42.8±9.0 NS*
Stage
IB1 8 5 NS
�
IB2 2 5
IIA 6 6
Cell types
SCC 12 13 NS
�
Others 4 3
Tumor size in diameter 3.4±1.1 4.1±1.5 NS*
Table 3. Comparisons of clinical variables in patients showing
stable disease to neoadjuvant chemotherapy
SD, stable disease; RS, radical surgery group treated by neoadjuvant
chemotherapy plus radical surgery; RT, radiotherapy group treated by
neoadjuvant chemotherapy plus radiotherapy; SCC, squamous cell car-
cinoma; NS, not statistically significant difference.
*, Mann-Whitney U test; 
� , Fisher’s exact test.
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Fig. 3. Survival estimation by Kaplan Meier’s method according
to definite therapy following neoadjuvant chemotherapy in patients
who showed stable disease after neoadjuvant chemotherapy. Five
year survival estimation of stable disease in RS and RT group was
76.4% vs. 37.5%, and 10 yr survival estimation was 76.4% vs. 25%.
This difference was statistically significant (p=0.0111) by Log rank
test. 
NACT, neoadjuvant chemotherapy; RS, radical surgery group
treated by neoadjuvant chemotherapy plus radical surgery; RT,
radiotherapy group treated by neoadjuvant chemotherapy plus
radiotherapy.Neoadjuvant Chemotherapy Against Uterine Cervical Cancer 687
Prognostic factors
In the RS group, 11 variables (age, stage, tumor size, tumor
growth pattern, histologic type, invasion depth, lymphovas-
cular invasion, lymph node metastasis, surgical margin, para-
metrial extension, chemoresponse) were evaluated for their
correlation with survival. Among these prognostic factors, age
(≥45 yr), lymphovascular invasion, invasion depth ≥7 mm,
lymph node metastasis were significantly associated with over-
all survival (Table 2). In multivariate analyses using Cox regre-
ssion hazard model, lymph node metastasis was only an inde-
pendent prognostic variable associated with overall survival
in RS group (Table 4). In whole series, conversion to radio-
therapy due to stable disease after neoadjuvant chemothera-
py was the most significant prognostic variable (Table 5).
DISCUSSION
Concurrent chemoradiotherapy has probably become a ‘stan-
dard of care’ for women with locally advanced disease. This
is supported by a National Cancer Institute Alert based on
the results of five randomized trials, stating ‘‘strong consider-
ation should be given to the incorporation of chemotherapy
into radiotherapy in women who require radiotherapy for the
treatment of cervical cancer’’. However, we still have clinical
dilemma especially in young patients with bulky stage IB,
IIA cervical cancer. Under the option of concurrent chemo-
radiotherapy, the patients will lose their sexual functions and
experience menopause. However, if primary radical surgery
is chosen, the patients also receive post-operative radiothera-
py in the majority of cases. For these reasons, neoadjuvant
chemotherapy followed by radical surgery might be still con-
sidered to be an attractive treatment option.
Tumor size of cervical carcinoma is an important prognos-
tic factor. The larger tumors are less likely to respond to radio-
therapy because their large hypoxic tumor cell population
reduces radiosensitivity. In an attempt to further delineate
the wide spectrum of behavior of Stage IB cervical cancer,
FIGO staging of cervical cancer was modified in August 1995.
FIGO established the classifications of stage IB1 (<4 cm) and
IB2 (≥4 cm). Traditional therapeutic strategies for the treat-
ment of stage IB2 cervical carcinoma have yielded disappoint-
ing results. Although the 5 yr survival rate exceeds 90% for
patients with stage IB1 disease, 5 yr survival is only 60 to
70% in patients with stage IB2 disease (7, 15). For these rea-
sons, the most effective therapeutic strategies for bulky locally
advanced cervical carcinoma, especially stage IB to IIA remain
uncertain. Previously, neoadjuvant chemotherapy followed
by radical surgery showed survival benefits in many retrospec-
tive as well as in several randomized controlled trials (9-12,
16-23). Despite these randomized trials and retrospective
studies, it is still unclear whether neoadjuvant chemothera-
py is effective for the treatment of locally advanced cervical
cancer. This is due to that most of retrospective studies in-
cluded only the patient groups treated by radical surgery fol-
lowing neoadjuvant chemotherapy, which likely has the pos-
sibility of selection bias by excluding cases treated by radio-
therapy after neoadjuvant chemotherapy due to poor chemo-
response. Furthermore, some of these randomized controlled
trials include too wide range of disease stages, even advanced
stages (IIB, IIIA, IIIB) which cannot be treated by radical
surgery if there is no sufficient chemoresponse.
The probability of survival benefits of neoadjuvant chemo-
therapy depends on high chemoresponsiveness. The response
rate to neoadjuvant chemotherapy was found to be 42 to
85% in randomized controlled trials of neoadjuvant chemo-
therapy settings (9-13, 24). Our study showed 66% of over-
all clinical response rates including 16% complete response,
which are compatible with previous reports. Because 15-40%
of patients treated by neoadjuvant chemotherapy result in
either stable disease or progressive disease, optimal treatment
of these groups of patients is considered of importance.
When our group adopted a neoadjuvant chemotherapy-
based therapeutic strategy, we thought that neoadjuvant che-
motherapy followed by radiotherapy might also have similar
survival benefits even in chemoresistant cases. For this rea-
son, we chose either radiotherapy or radical surgery in oper-
ation-available patients with poor chemoresponse without
specific criteria. In this retrospective study, however, there
detected a significant survival difference in 10 yr survival rates
between the RS group (76.4%) with stable disease and the
RT group (25%) with stable disease (Table 4, Fig. 4). These
patients showed similar clinical characteristics in comparison.
Because there is no information about lymph node metasta-
sis, lymphovascular invasion, and invasion depth of the RT
Variables Odds ratio 95% CI p-value*
Age 1.093 0.991-1.205 0.075
LVS involvement 0.000 0.000-4.083 0.950
Invasion depth 1.085 0.917-1.283 0.344
LN metastasis 5.702 1.029-31.596 0.046
Table 4. Multivariate analysis of prognostic factors in radical
surgery following neoadjuvant chemotherapy
CI, confidence interval; LVS, lymphvascular space; LN, lymph node.
*, Cox regression hazard model.
Variables Odds ratio 95% CI p-value*
Age 1.055 0.992-1.123 0.090
Tumor size 0.929 0.503-1.714 0.814
Cell type 2.144 0.397-11.585 0.376
Chemoresponse 0.323 0.070-1.494 0.148
Conversion to 4.638 1.240-17.346 0.023
radiotherapy
�
Table 5. Multivariate analysis of prognostic factors in whole series
CI, confidence interval.
*, Cox regression hazard model; 
� , conversion to radiotherapy for definite
therapy due to stable disease after neoadjuvant chemotherapy.group, the prognostic factors could not be compared in two
groups (RS vs. RT).
Previous two retrospective studies showed similar poor
outcomes in patients treated by radiotherapy after neoadju-
vant chemotherapy due to poor chemoresponse. In one report,
59 patients with bulky (≥4 cm) stage IB or IIA cervical car-
cinoma were treated by neoadjuvant chemotherapy, among
whom 51 underwent radical surgery and the remaining 8
were treated by definitive radiotherapy. The 5 yr survival rate
of these patients who received hysterectomy was 80.3% while
only 1 of the 8 patients treated by radiotherapy without hys-
terectomy survived (survival rate, 12.5%). Of the 7 patients
receiving hysterectomy after chemotherapy despite clinical
poor response, only 3 patients died (survival rate, 43%) (25).
In the other report, 42 patients with FIGO stage IB-IIA bulky
(≥4 cm), IIB-IIIB cervical adenocarcinoma were treated by
neoadjuvant chemotherapy. The 33 chemoresponders (79%)
received laparotomy, among them 29 patients were feasible
for radical surgery. The remaining 9 nonresponders received
radiotherapy, but all of them were dead, as compared to che-
moresponder groups (5 yr survival rate, 84%) (26).
Although chemotherapeutic agents can act as a radiosensi-
tizer in concurrent chemoradiotherapy, pre-exposure to che-
motherapeutic agents prior to radiation might render tumor
cells to alter their biological systems. Cervical tumors are rapidly
proliferating with a median potential doubling time of only
4-4.5 days and a relatively high growth fraction (27). After
an effective chemotherapy, tumors can shrink, but in a short
time grow again at a more accelerated speed. After tumor cell
divisions, tumor volume could be restored and tumor cells
can obtain resistance to chemotherapeutic drugs and even to
conventionally fractionated radiotherapy, which possibly results
from altered tumor cell growth kinetics (13). If tumor cells
are cross-resistant to chemotherapy and radiotherapy, the fac-
tors, such as the duration of chemotherapy and the delay to
radiotherapy for the overall treatment time might have an
impact on prognosis (13). 
Benedetti-Panici et al. reported that neoadjuvant chemo-
therapy is of benefit only to Stage IB2, or IIB, not to Stage
III (9). Sardi et al. also showed survival benefit only in Stage
IB2 cervical cancer, not in Stage IB1 (10, 11). Similarly, one
Japanese group demonstrated that radiotherapy is not bene-
ficial for stages IIB, IIIA, IIIB, but somewhat helpful only for
patients with good chemoresponse treated by radical surgery
(12). In our study, patients with bulky stage IB to IIA cervi-
cal cancer (≥4 cm) showed a good long term survival (5 yr
survival rate, 91.7%; 10 yr survival rate, 83.3%). This appears
to be better than survival of previous conventional treatment
(7, 15). However, the long term survival of patients with non-
bulky tumor (<4 cm) looked not improved. These are com-
patible with previous randomized controlled studies (9-11).
It is likely that neoadjuvant chemotherapy strategy might
be limited to bulky stage IB to IIA and perhaps IIB cervical
cancer.
In summary, survival benefits of neoadjuvant chemother-
apy followed by radical surgery are observed only in bulky
(≥4 cm) stage IB to IIA cervical cancer, but not in non-bulky
stage IB to IIA. In chemoresistant cases, patients undergo-
ing radiotherapy after chemotherapy showed poorer survival
rates than patients with radical surgery. Our retrospective
study shows that radiotherapy after chemotherapy makes
survival outcome deteriorated in chemoresistant patients.
Thus, radical surgery might be better treatment option even
though patients with stage IB to IIA cervical carcinoma show
chemoresistance to neoadjuvant chemotherapy. 
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